אינטגרילין 2 מגמל

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

EPTIFIBATIDE

Disponible depuis:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

Code ATC:

B01AC16

forme pharmaceutique:

תמיסה להזרקה

Composition:

EPTIFIBATIDE 2 MG/ML

Mode d'administration:

תוך-ורידי

Type d'ordonnance:

מרשם נדרש

Fabriqué par:

SCHERING-PLOUGH LABO. N.V , BELGIUM

Groupe thérapeutique:

EPTIFIBATIDE

Domaine thérapeutique:

EPTIFIBATIDE

indications thérapeutiques:

Integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-Q-wave myocardial infarction. Integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. Integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (PTCA) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). Integrilin is intended for use with aspirin and heparin.

Date de l'autorisation:

2013-10-31